Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.47 |
| ▸ | TACR2 | P21452 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2451921 | 0.90 | ADRA1D (0.44) | SIGMAR1OPRM1KCNH2ADRA1DADRA1A | |
| SCHEMBL2452284 | 0.89 | SIGMAR1 (0.55) | SIGMAR1OPRM1KCNH2TACR2TACR1 | |
| SCHEMBL2452349 | 0.87 | SIGMAR1 (0.52) | SIGMAR1OPRM1KCNH2DRD2HTR2A | |
| SCHEMBL2453500 | 0.79 | SIGMAR1 (0.53) | SIGMAR1OPRM1KCNH2TACR2TACR1 | |
| SCHEMBL2454408 | 0.78 | SIGMAR1 (0.44) | SIGMAR1OPRM1KCNH2ADRA1DADRA1A | |
| SCHEMBL2446498 | 0.77 | SIGMAR1 (0.49) | SIGMAR1OPRM1KCNH2TACR2TACR1 | |
| SCHEMBL2451570 | 0.75 | SIGMAR1 (0.44) | SIGMAR1OPRM1KCNH2ADRA1DADRA1A | |
| SCHEMBL11367275 | 0.74 | SIGMAR1 (0.50) | SIGMAR1OPRM1KCNH2TACR2TACR1 | |
| SCHEMBL18730487 | 0.74 | SIGMAR1 (0.66) | SIGMAR1ADRA1DADRA1AADRA1B | |
| SCHEMBL2449728 | 0.73 | SIGMAR1 (0.48) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364982-A1 | Spiro-piperidine compounds as chemokine receptor antagonists and medicinal use thereof | ONO Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | SIGMAR1 225/4885OPRM1 436/4885KCNH2 640/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | SIGMAR1 225/4885OPRM1 436/4885KCNH2 640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.